Press releases

Mölndal, May 15, 2019 – Vicore Pharma Holding (publ) publishes the interim report for the first quarter 2018. Read more

Mölndal, April 23, 2019 - Vicore Pharma AB (publ) a leading rare diseases pharmaceutical company today announces that it has selected diffuse systemic sclerosis (dSSc)… Read more

The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, with registered office in Mölndal, are summoned to the Annual General Meeting on Wednesday… Read more

Mölndal, April 12, 2019 - Vicore Pharma Holding AB (publ) announces today that the annual report for 2018 has been published and is available on… Read more

Mölndal, March 15, 2019 – Vicore Pharma Holding (publ) (ticker: VICO) publish the year-end report for 2018 Read more

Mölndal, February 13, 2019 - Vicore Pharma Holding AB (publ) has decided to postpone the publication of the year-end report for 2018. The year-end report… Read more

Read more

The shareholders in Vicore Pharma Holding AB (publ), reg. no. 556680-3804 (the “Company”), are hereby summoned to attend an Extraordinary General Meeting (“EGM”) on Monday… Read more

NOT FOR DISTRIBUTION OR PUBLIC RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UK, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN… Read more

Mölndal, November 8, 2018 – Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the third quarter 2018. Read more

Not to be released, publication or distribution, directly or indirectly, in or to the United States, Australia, Hong Kong, Singapore, Canada, Japan, New Zealand or… Read more

Mölndal, October 22, 2018 - Due to personal reasons, Göran Wessman has chosen to resign from the Board of Directors of Vicore Pharma Holding AB… Read more

Mölndal, October 9, 2018 - Vicore Pharma Holding AB (publ) (”Vicore” or the ”Company”) has completed the new share issue with pre-emption rights for existing… Read more

Mölndal, September 26, 2018 - Vicore Pharma Holding AB (publ) has decided to postpone the publication of the interim report for the third quarter 2018.… Read more

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, HONG KONG, SWITZERLAND, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR… Read more

September 17, 2018 - Vicore Pharma (publ) announced today it has appointed Rohit Batta as Chief Medical Officer effective November 26 and Göran Tornling as… Read more

The Board of Directors of Vicore Pharma Holding AB (publ) (”Vicore”) informs about the time plan for the rights issue (the ”Rights issue”) that was… Read more

Vicore Pharma (publ) today announced that it will expand its clinical program of lead compound C21, for the treatment of idiopathic pulmonary fibrosis (IPF), to… Read more

The board of directors of Vicore Pharma Holding AB (”Vicore”) has on August 29, 2018 appointed Dr. Carl-Johan Dalsgaard as new CEO of Vicore. Carl-Johan… Read more

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the second quarter 2018. Read more

Read more

Today, Wednesday, August 15, is the last day Vicore Pharma Holding (publ) (ticker: VICO) share is traded including the right to dividend shares in I-Tech… Read more

The Extra General Meeting (EGM) of Vicore Pharma Holding AB (publ) was held today August 13, 2018. The EGM passed resolutions regarding, among other thing,… Read more

The shareholders in Vicore Pharma Holding AB (publ), reg. no. 556680-3804 (the “Company”), are hereby summoned to attend an Extraordinary General Meeting (“EGM”) on Monday… Read more

Vicore Pharma Holding AB (publ) ("Vicore" or "The Company") has entered into an agreement to acquire INIM Pharma AB ("INIM"), a Swedish biopharmaceutical company developing… Read more

Read more

The shareholders in Vicore Pharma Holding AB (publ), 556680-3804, are hereby summoned to attend the Annual General Meeting on June 13, 2018 at 4:00 p.m.… Read more

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the first quarter 2018. Read more

Read more

Vicore Pharma Holding (publ) (ticker: VICO) today announces the approval from the British Medicines Agency MHRA and the Ethics Committee for London and Surrey to… Read more

Vicore Pharma Holding (publ) (ticker: VICO) can today announce that the annual report for 2017 is now available on the company's website; www.vicorepharma.com Read more

The shareholders in Vicore Pharma Holding AB (publ), 556680-3804, are hereby summoned to attend the Annual General Meeting on Tuesday, May, 8, 2018 at 3:00… Read more

Vicore Pharma Holding (publ) (ticker:VICO) can today announce that preclinical data with C21 demonstrating good results has been accepted for publication. Read more

Read more

Read more

Read more

Vicore Pharma Holding AB (publ) (ticker: VICO) announces a share increase in I-Tech AB. Read more

Vicore Pharma (publ) (ticker VICO) has today published an updated reference list on the latest preclinical studies with the drug candidate C21. Two recent published… Read more

Vicore Pharma Holding (publ) (ticker:VICO) has increased its holding in I-Tech through a share issue. Read more

Vicore Pharma Holding (publ) (ticker:VICO) announces that an application to start a Phase IIa study with C21 in patients suffering from Idiopathic Pulmonary Fibrosis has… Read more

Vicore Pharma Holding (publ) (ticker:VICO). It is with great regret we today inform of board member Göran Arvidson sudden and unexpected death. Read more

Vicore Pharma will present at the Biotech and Money Inv€$tival Showcase in partnership with Jefferies and host one-to-one meetings at the Jefferies 2017 London Healthcare… Read more

Vicore Pharma Holding publish the interim report for the third quarter, 2017. Read more

Vicore Pharma (publ) (ticker VICO) has today published an updated reference list on the latest studies with the drug candidate C21. Three recent review articles,… Read more

Vicore Pharma AB (publ) (ticker: VICO) can today announce positive results from the in-depth analysis of the Phase I extension study with its candidate drug… Read more

Vicore Pharma Holding publish the interim report for the second quarter, 2017. Read more

Vicore Pharma AB (publ) (ticker: VICO) can today announce positive results from the Phase I extension study with its candidate drug C21. Read more

Vicore Pharma AB (publ) (ticker: VICO) today announced that they strengthen the organization with three new key recruitments. Read more

Read more

Newly appointed Chairman of the Board of Vicore Pharma Holding (ticker: VICO), Leif Darner has acquired 100,000 shares from Protem Wessman AB, controlled by Göran… Read more

Vicore Pharma AB (ticker: VICO), a global biotech company developing drugs that act through the AT2 receptor in the renin angiotensin system, today announced that… Read more

The Annual General Meeting (AGM) of Vicore Pharma Holding AB (publ) was held today May 10, 2017. The AGM passed resolutions regarding, among other thing,… Read more

Vicore Pharma Holding publish the interim report for the period January-March, 2017. Read more

We achieved the milestones we determined for 2016. Now, we will continue to develop C21 into a future drug for the treatment of idiopathic pulmonary… Read more

Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, hereby gives notice to shareholders to attend the Annual General Meeting on Wednesday 10 May 2017 at… Read more

Read more

A BioMAP® report comparing Vicore Pharma’s drug candidate C21 to two approved drugs for IPF shows strong and competitive results Read more

The Board of Directors of Vicore Pharma Holding AB has resolved on two directed share issues, one pursuant to authorization from the general annual meeting… Read more

Vicore Pharma has today announced that it has developed new drug molecules that selectively stimulate the AT2 receptor (AT2R agonism) in the Renin-Angiotensin-System. Based on… Read more

US Food and Drug Administration (FDA) has granted orphan drug status for Vicore Pharma's lead compound C21 for the treatment of idiopathic pulmonary fibrosis (IPF). Read more

Vicore Pharma has completed the two-part Phase I study in healthy male volunteers and have thereby passed an important milestone in the company's development. Read more

The first study showing a cardioprotective effect of the AT2-receptor agonist, C21, in cancer treatment. Read more

The European Commission has granted orphan drug status for Vicore Pharma’s lead compound C21 for the treatment of idiopathic pulmonary fibrosis (IPF). Read more

- Dr Chow et al, Melbourne: C21 has an anti-atherosclerotic effect in animal models with diabetes. - Dr Liu et al, Beijing: C21 protects the… Read more

Vicore Pharma reports the conclusion of the clinical conduct of its first Phase I trial with C21. The study was conducted on male healthy volunteers… Read more

Vicore Pharma Holdings financial asset, I-Tech recently won a prestigious prize arranged by the European Marine Engineering awards for their antifouling substance, Selektope®. Read more… Read more

Vicore Pharma H., holds 17% of the shares in I-Tech AB. Final sign-off of the antifouling active substance Selektope® by the European Commission coincides the… Read more

The antifouling biocide Selektope®has been endorsed by the EU Standing Committee on Biocidal Products and will be approved EU wide from the 1st of January… Read more

Mintage Scientifics holding I-Tech strengthens its commercial and industrial capabilities by appointing Oliver Weigenand as Chief Operating Officer (COO). Read more

I-Tech has been notified that Selektope®, a marine biocide used to improve ship hull performance and reduce maintenance, has been approved for use in China Read more

I-Tech has entered into a non-exclusive supply agreement with Chugoku Marine Paints Ltd (CMP) for use of I-Tech’s proprietary product, Selektope®, in commercial antifouling paints.… Read more

Mintage Scientifics minority interest holding, I-Tech, the originator of Selektope®, a marine biocide used to improve ship hull performance and reduce maintenance, has been notified… Read more

Vicore Pharma today announced funding support from Fast Forward, LLC. The funding award will help support the research of angiotensin AT2-receptor agonists for the potential… Read more